Trial Information
A Study of the Pharmacodynamic Effects of Anti-vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies
Inclusion Criteria:
- Eligibility
- Patients who are receiving single agent anti-VEGF therapy
- Signed written informed consent
- Patients with measurable pulmonary malignancy (primary or metastatic) as determined
by RECIST will undergo assessment of pulmonary function
- Patients with a known allergy to intravenous contrast used in fluorescein and
indocyanine green angiography will be exempt from these investigations but will
undergo other study assessments
Exclusion Criteria:
- None
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Authority:
Singapore: Domain Specific Review Boards
Study ID:
MC02/15/07
NCT ID:
NCT00978926
Start Date:
September 2009
Completion Date:
Related Keywords:
- Advanced Malignancy
- Anti-Vascular Endothelial growth factor
- Neoplasms